June 24, 2022
Bulletin interne de l'Institut Pasteur
COVID-19: Identification of broadly SARS-CoV-2 neutralizing monoclonal antibodies
Although the different SARS-CoV-2 variants currently in circulation are undoubtedly less severe in vaccinated individuals in the general population, immunocompromised people are at greater risk of developing severe forms of COVID-19. Monoclonal antibodies currently offer the best approach, both as a preventive and curative treatment for these patients. Scientists from the Institut Pasteur and Inserm identified two potent neutralizing antibodies from convalescent COVID-19 individuals that proved effective against SARS-CoV-2 variants of concern. These human antibodies are prime candidates for the development of immunotherapies to prevent severe forms and/or treat COVID-19. The findings were published in The Journal of Experimental Medicine.